- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04132102
To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
Study Overview
Detailed Description
This is an open-label, sing-arm phase IV clinical study which will recruit about 20 patients in China.
The main objective of this study is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.
Target patient population:Locally advanced (IIIB) or metastatic (stage IV) immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive mutation patients, whom previously untreated or received platinum-based doublet chemotherapy as first-line treatment with subsequent disease progression, and had to be eligible for second-line treatment.
Investigational product, the dose and administration method: Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1 (CTCAE 5.0).
Study assessment: The collected data include the patient's demographic characteristics, information needed to determine whether the patient is eligible (including medical history, attributes of previous and current disease, and EGFR mutation status in tumor tissues), efficacy of objective response rate(ORR), progression-free survival (PFS), overall survival (OS), and safety (including serious adverse events and dose change-induced adverse events).
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Contact:
- Yongfeng Yu, Master
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Selected patients must meet all of the following standards:
- The patient's or his/her legal representative's has signed and dated written informed consent before any specific study procedure.
- The patient is above 18 years old.
- Locally advanced (IIIB) or metastatic (stage IV) immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive mutation patients, whom previously untreated or received platinum-based doublet chemotherapy as first-line treatment with subsequent disease progression, and had to be eligible for second-line treatment.
- The patient has NOT previously received EGFR-TKI treatment.
- ECOG Performance Status Score is 0~2.
- The patient has sufficient bone marrow and organ function proved by baseline complete plasma count, plasma biochemistry and urinary biochemistry tests.
- Female patients of childbearing age must use adequate contraceptives, and breastfeeding is not allowed.
Male patients must voluntarily to use contraceptives.
Exclusion criteria
Selected patients can not meet any one of the following standards:
- The patient has received EGFR-TKI treatment.
- The patient has any severe or uncontrolled systemic signs of illness, including uncontrolled hypertension, active easy-bleeding constitution, active infection, or significantly impaired function of bone marrow or organs, which researchers believe can significantly change the patient's risk/benefit balance.
- The patient has symptomatic central nervous system (CNS) metastases.
- The patient has the history of interstitial pneumonia, or radiation pneumonia which needs steroid treatment.
- The patient still has unrecovered toxic reaction with ≥ grade 3 (CTCAE5.0) caused by previously received treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afatinib treatment group
This is an open-label, sing-arm phase IV clinical study
|
Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors.
Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day.
If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Up to 12 months
|
PFS refers to the time from initial prescription of afatinib to the time of disease progression or death recorded in CRF in this study, no matter whether the patient withdraw from the treatment before disease progression or receive other anti-cancer treatment or not.
For the patient without progression or death at the time of analysis, the latest assessment date will be used as interpolation (censoring).
(Or, if there's no tumor assessment after baseline visit, baseline visit date will be used
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 12 months
|
ORR refers to the incidence of complete remission (CR) or partial remission (PR) (determined according to RECIST1.1 standards)
|
Up to 12 months
|
Overall survival (OS)
Time Frame: Up to 12 months
|
OS refers to the time from the patient entering into the group to the time of death.
When it comes to the analysis of patients with unknown survival status, the last date when learning of the patient's survival will be used as interpolation (censoring)
|
Up to 12 months
|
Rate of SAEs, dose change-induced AEs, and AEs of particular concerns.
Time Frame: Up to 12 months
|
Serious adverse events [SAEs], dose change-induced AEs, and AEs of particular concerns.
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XK-LS-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Squamous Cell Carcinoma
-
Xuzhou Central HospitalUnknownLung Squamous Cell Carcinoma
-
Second Xiangya Hospital of Central South UniversityShanghai OrigiMed Co., Ltd.RecruitingLung Squamous Cell CarcinomaChina
-
Xuzhou Medical UniversityRecruitingLung Squamous Cell CarcinomaChina
-
National Cancer Institute (NCI)CompletedRecurrent Lung Squamous Cell Carcinoma | Stage IV Lung Squamous Cell Carcinoma AJCC v7United States
-
Hunan Province Tumor HospitalRecruitingAdvanced Lung Squamous Cell CarcinomaChina
-
Sichuan UniversityInnovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Lung Squamous Cell CarcinomaChina
-
Guangdong Association of Clinical TrialsUnknownLung Squamous Cell Carcinoma Stage IVChina
-
First Affiliated Hospital of Zhejiang UniversityRecruitingNeoadjuvant Therapy | Immunotherapy | Lung Squamous Cell CarcinomaChina
-
Eli Lilly and CompanyCompletedCarcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IVUnited States
-
National University Hospital, SingaporeUnknownSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the LungSingapore
Clinical Trials on Afatinib
-
Boehringer IngelheimCompleted
-
Centre Leon BerardBoehringer IngelheimCompletedHead and Neck Squamous Cell CarcinomaFrance
-
University of ChicagoNational Cancer Institute (NCI)RecruitingRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral CancerUnited States
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungGreece
-
Boehringer IngelheimCompletedNeuroectodermal Tumors | RhabdomyosarcomaUnited States, Spain, Canada, Germany, Italy, United Kingdom, Australia, Austria, Denmark, Faroe Islands, France, Netherlands
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimApproved for marketing
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimNo longer available
-
University College, LondonBoehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungUnited Kingdom